International journal of clinical oncology · 2025
Radiotherapy with or without chemotherapy for T2N0 hypopharyngeal cancer: an analysis of the head and neck cancer registry of Japan.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nishimura Ari, Fukuda Naoki, Kawakita Daisuke, Kitayama Megumi, Nibu Ken-Ichi, Yoshimoto Seiichi, Uemura Hirokazu, Kitahara Tadashi
Аннотация
PURPOSE: This retrospective study compared the outcomes of radiotherapy (RT) and chemoradiotherapy (CRT) in patients with T2N0 hypopharyngeal cancer.
METHODS: We analyzed patients with T2N0 hypopharyngeal squamous cell carcinoma treated with RT or CRT between 2011 and 2016 using data from the Head and Neck Cancer Registry of Japan.
RESULTS: Among 53,512 patients, 457 with T2N0 disease received RT (n = 165) or CRT (n = 292; median follow-up, 41.8 months; median age, 70 years). Tumor sites included the pyriform sinus (72.9%), postcricoid region (12.3%), posterior wall (11.8%), and unknown (3.1%). The groups differed in terms of age and alcohol use. Before weighing, CRT was associated with longer PFS and a lower cumulative incidence of locoregional recurrence compared with RT. However, in the IPTW-adjusted analysis, CRT did not significantly improve OS (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.59-1.62) or PFS (HR, 0.79; 95% CI, 0.53-1.16) compared with RT. PFS was associated with alcohol/smoking history, performance status, and primary site of the tumor.
CONCLUSION: In T2N0 hypopharyngeal cancer, CRT reduced the locoregional recurrence compared to RT. However, CRT did not confer a significant OS or PFS advantage over RT after adjustment for baseline imbalances. RT alone may, therefore, be a reasonable definitive treatment option for selected patients.
METHODS: We analyzed patients with T2N0 hypopharyngeal squamous cell carcinoma treated with RT or CRT between 2011 and 2016 using data from the Head and Neck Cancer Registry of Japan.
RESULTS: Among 53,512 patients, 457 with T2N0 disease received RT (n = 165) or CRT (n = 292; median follow-up, 41.8 months; median age, 70 years). Tumor sites included the pyriform sinus (72.9%), postcricoid region (12.3%), posterior wall (11.8%), and unknown (3.1%). The groups differed in terms of age and alcohol use. Before weighing, CRT was associated with longer PFS and a lower cumulative incidence of locoregional recurrence compared with RT. However, in the IPTW-adjusted analysis, CRT did not significantly improve OS (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.59-1.62) or PFS (HR, 0.79; 95% CI, 0.53-1.16) compared with RT. PFS was associated with alcohol/smoking history, performance status, and primary site of the tumor.
CONCLUSION: In T2N0 hypopharyngeal cancer, CRT reduced the locoregional recurrence compared to RT. However, CRT did not confer a significant OS or PFS advantage over RT after adjustment for baseline imbalances. RT alone may, therefore, be a reasonable definitive treatment option for selected patients.